{"totalCount":2,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT07108153","orgStudyIdInfo":{"id":"SION-719-201"},"organization":{"fullName":"Sionna Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta","officialTitle":"A Phase 2a Randomized, Double-blind, Placebo-controlled Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Physician-prescribed TrikaftaÂ® in People With Cystic Fibrosis Who Are Homozygous for the F508del Mutation","acronym":"PreciSION CF"},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-11-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-07","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-07","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-07-18","studyFirstSubmitQcDate":"2025-07-31","studyFirstPostDateStruct":{"date":"2025-08-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-19","lastUpdatePostDateStruct":{"date":"2025-12-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sionna Therapeutics Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta."},"conditionsModule":{"conditions":["Cystic Fibrosis (CF)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":16,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Crossover Treatment Sequence 1: SION-719 followed by placebo-to-match SION-719","type":"EXPERIMENTAL","description":"Participants receive SION-719 for one treatment period, and placebo to match SION-719 for the other treatment period. All participants will remain on their physician-prescribed Trikafta as background therapy throughout the study.","interventionNames":["Drug: SION-719","Drug: Placebo-to-match SION-719"]},{"label":"Crossover Treatment Sequence 2: Placebo-to-match SION-719 followed by SION-719","type":"EXPERIMENTAL","description":"Participants receive placebo to match SION-719 for one treatment period and SION-719 for the other treatment period. All participants will remain on their physician-prescribed Trikafta as background therapy throughout the study.","interventionNames":["Drug: SION-719","Drug: Placebo-to-match SION-719"]}],"interventions":[{"type":"DRUG","name":"SION-719","description":"All participants receive SION-719, as specified by their treatment sequence assignment","armGroupLabels":["Crossover Treatment Sequence 1: SION-719 followed by placebo-to-match SION-719","Crossover Treatment Sequence 2: Placebo-to-match SION-719 followed by SION-719"]},{"type":"DRUG","name":"Placebo-to-match SION-719","description":"All participants receive placebo to match SION-719, as specified by their treatment sequence assignment","armGroupLabels":["Crossover Treatment Sequence 1: SION-719 followed by placebo-to-match SION-719","Crossover Treatment Sequence 2: Placebo-to-match SION-719 followed by SION-719"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] when SION-719 is administered to people with cystic fibrosis (CF) who are taking a standard stable dose of physician-prescribed Trikafta","description":"Adverse events will be assessed by Common Terminology Criteria for Adverse Events (CTCAE), v. 5.0","timeFrame":"Day 1 through day 57"}],"secondaryOutcomes":[{"measure":"Change from baseline in sweat chloride levels","description":"Changes from baseline in sweat chloride levels will be analyzed with mixed model repeated measures (MMRM) methods.","timeFrame":"Baseline to Day 15 in each treatment period"},{"measure":"Concentration of SION-719 in plasma and change of concentration of SION-719 in plasma.","description":"Concentrations of plasma SION-719 will be evaluated at each collected timepoint and summarized using descriptive statistics.","timeFrame":"Day 1 through day 57"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of CF with F508del homozygous genotype based on documented CFTR genotype laboratory report.\n* Adherent to physician-prescribed Trikafta, as assessed by the Investigator, for at least 3 months prior to the Screening visit, taken at the recommended dose without modifications and on the regimen described in the current prescribing information.\n* Stable CF disease without pulmonary exacerbation within 28 days before Baseline or acute non-CF-related illness within 14 days before Baseline.\n\nExclusion Criteria:\n\n* Participant has clinically significant current or recurrent illness, other than CF\n* Participant has a history of malignancy, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of recurrence for at least 1 year.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"VP, Head of Medical Affairs & Patient Advocacy","role":"CONTACT","phone":"617-819-1389","email":"medinfo@sionnatx.com"}],"overallOfficials":[{"name":"Medical Director","affiliation":"Sionna Therapeutics Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"National Jewish Health","status":"RECRUITING","city":"Denver","state":"Colorado","zip":"80206","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"University of Iowa","status":"RECRUITING","city":"Iowa City","state":"Iowa","zip":"52242","country":"United States","geoPoint":{"lat":41.66113,"lon":-91.53017}},{"facility":"Johns Hopkins","status":"RECRUITING","city":"Baltimore","state":"Maryland","zip":"21205","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Boston Children's Hospital","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Washington University","status":"RECRUITING","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"New York Medical College","status":"RECRUITING","city":"Hawthorne","state":"New York","zip":"10532","country":"United States","geoPoint":{"lat":41.10732,"lon":-73.79597}},{"facility":"Columbia University","status":"RECRUITING","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"University Hospital of Cleveland","status":"RECRUITING","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Medical University of South Carolina","status":"RECRUITING","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"University of Washington","status":"RECRUITING","city":"Seattle","state":"Washington","zip":"98195","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Royal Prince Alfred Hospital","status":"RECRUITING","city":"Camperdown","state":"New South Wales","zip":"2050","country":"Australia","geoPoint":{"lat":-33.88965,"lon":151.17642}},{"facility":"Gold Coast University Hospital","status":"RECRUITING","city":"Southport","state":"Queensland","zip":"4215","country":"Australia","geoPoint":{"lat":-27.96724,"lon":153.39796}},{"facility":"Monash University","status":"NOT_YET_RECRUITING","city":"Melbourne","state":"Victoria","zip":"3004","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D003550","term":"Cystic Fibrosis"}],"ancestors":[{"id":"D010182","term":"Pancreatic Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D007232","term":"Infant, Newborn, Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07035990","orgStudyIdInfo":{"id":"SION-451-101"},"secondaryIdInfos":[{"id":"ACTRN12624000849895","type":"REGISTRY","domain":"Australian New Zealand Clinical Trials Registry"},{"id":"ACTRN12624000848505","type":"REGISTRY","domain":"Australian New Zealand Clinical Trials Registry"}],"organization":{"fullName":"Sionna Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.","officialTitle":"A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of SION-451, and Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants."},"statusModule":{"statusVerifiedDate":"2025-08","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-07-23","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-06-04","studyFirstSubmitQcDate":"2025-06-16","studyFirstPostDateStruct":{"date":"2025-06-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-02","lastUpdatePostDateStruct":{"date":"2025-09-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sionna Therapeutics Inc.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The purpose of Parts D and E of this Phase 1 study are to evaluate the safety, tolerability, and pharmacokinetics of multiple dose combinations of SION-451 and complementary modulators SION-2222 and SION-109 in healthy participants.","detailedDescription":"This is a Phase 1 randomized, double-blind, placebo-controlled study. Parts D and E will evaluate the safety, tolerability, and pharmacokinetics of multiple dose combinations of SION-451 and complementary modulators SION-2222 and SION-109 in healthy participants. Parts A, B, and C of this study have completed dosing.\n\nPart D will involve multiple dosing of SION-451 and SION-2222 in combination. Part E will involve multiple dosing of SION-451 and SION-109 in combination."},"conditionsModule":{"conditions":["Cystic Fibrosis (CF)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":144,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"SION-451 + SION-2222","type":"EXPERIMENTAL","description":"All participants who receive SION-451 in combination with SION-2222","interventionNames":["Drug: SION-451","Drug: SION-2222"]},{"label":"Placebo matched to SION-451 and SION-2222","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo SION-451","Drug: Placebo SION-2222"]},{"label":"SION 451 + SION 109","type":"EXPERIMENTAL","description":"All participants who receive SION-451 in combination with SION-109","interventionNames":["Drug: SION-451","Drug: SION-109"]},{"label":"Placebo matched to SION-451 and SION-109","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo SION-451","Drug: Placebo SION-109"]}],"interventions":[{"type":"DRUG","name":"SION-451","description":"* Pharmaceutical form: tablet\n* Route of administration: oral","armGroupLabels":["SION 451 + SION 109","SION-451 + SION-2222"]},{"type":"DRUG","name":"SION-2222","description":"* Pharmaceutical form: capsule\n* Route of administration: oral","armGroupLabels":["SION-451 + SION-2222"]},{"type":"DRUG","name":"SION-109","description":"* Pharmaceutical form: tablet\n* Route of administration: oral","armGroupLabels":["SION 451 + SION 109"]},{"type":"DRUG","name":"Placebo SION-451","description":"Placebo matched to SION-451","armGroupLabels":["Placebo matched to SION-451 and SION-109","Placebo matched to SION-451 and SION-2222"]},{"type":"DRUG","name":"Placebo SION-2222","description":"Placebo matched to SION-2222","armGroupLabels":["Placebo matched to SION-451 and SION-2222"]},{"type":"DRUG","name":"Placebo SION-109","description":"Placebo matched to SION-109","armGroupLabels":["Placebo matched to SION-451 and SION-109"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] of SION-451 and SION-109 when administered in combination to healthy participants","description":"Adverse reactions to the study drug combination SION-451 and SION-109 will be measured.","timeFrame":"From Day 1 through day 21"},{"measure":"To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] of SION-451 and SION-2222 when administered in combination to healthy participants","description":"Adverse events to the study drug combination SION-451 and SION-2222 will be measured","timeFrame":"From Day 1 through day 21"}],"secondaryOutcomes":[{"measure":"Cmax of SION-451 and SION-2222 in plasma when administered in combination to healthy participants","timeFrame":"From Day 1 through day 17"},{"measure":"Tmax of SION-451 and SION-2222 in plasma when administered in combination to healthy participants","timeFrame":"From Day 1 through day 17"},{"measure":"AUC of SION-451 and SION-2222 in plasma when administered in combination to healthy participants","timeFrame":"From Day 1 through day 17"},{"measure":"t1/2 of SION-451 and SION-2222 in plasma when administered in combination to healthy participants","timeFrame":"From Day 1 through day 17"},{"measure":"Volume of distribution of SION-451 and SION-2222 in plasma when administered in combination to healthy participants","timeFrame":"From Day 1 through day 17"},{"measure":"Apparent total clearance of SION-451 and SION-2222 in plasma when administered in combination to healthy participants","timeFrame":"From Day 1 through day 17"},{"measure":"Cmax of SION-451 and SION-109 in plasma when administered in combination to healthy participants","timeFrame":"From Day 1 through day 17"},{"measure":"Tmax of SION-451 and SION-109 in plasma when administered in combination to healthy participants","timeFrame":"From Day 1 through day 17"},{"measure":"AUC of SION-451 and SION-109 in plasma when administered in combination to healthy participants","timeFrame":"From Day 1 through day 17"},{"measure":"t1/2 of SION-451 and SION-109 in plasma when administered in combination to healthy participants","timeFrame":"From Day 1 through day 17"},{"measure":"Volume of distribution of SION-451 and SION-109 in plasma when administered in combination to healthy participants","timeFrame":"From Day 1 through day 17"},{"measure":"Apparent total clearance of SION-451 and SION-109 in plasma when administered in combination to healthy participants","timeFrame":"From Day 1 through day 17"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy male or female adult participants aged 18 to 55 years, inclusive, at the time of consent.\n2. Weight of at least 45 kg and body mass index between 18.0 and 32.0 kg/m2, inclusive, at Screening.\n3. Participant is willing to abstain from alcohol, caffeine, smoking and nicotine-containing products for 72 hours prior to Day -1 through the duration of the study. Participant is willing to abstain from eating cruciferous vegetables, charcoal-grilled meats, and poppy seeds for 48 hours prior to dosing throughout the duration of the study.\n4. Participant has read, understood, and voluntarily provided written informed consent\n5. Participant has an understanding, ability, and willingness to fully comply with study procedures and restrictions.\n\nExclusion Criteria:\n\n1. Participant has clinically significant, in the opinion of the investigator, current or recurrent illness, such as cardiovascular (including but not limited to known structural cardiac abnormalities, family history of long QT syndrome, or cardiac syncope or recurrent, idiopathic syncope), neurologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine, or psychiatric disease or disorder, or other abnormality which may affect safety or clinical laboratory evaluations.\n2. Participant has a history of malignancy, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of recurrence for at least 1 year.\n3. Participant has clinically significant abnormalities, in the opinion of the investigator, on ECG, physical examination, or vital sign assessment at Screening or Day -1.\n4. Participant has any single reading of QTcF \\>470 ms (females) or \\>450 ms (males) at Screening or Day -1.\n5. Chronic or habitual alcohol (\\>10 standard drinks per week) or tobacco (\\>10 cigarettes per week) use or use of recreational drugs (\\>1 use per month). The Investigator may exclude a participant with lower levels of alcohol, tobacco, or recreational drug use based on discretion and the pattern or history of use.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Cecile LeCamus","role":"CONTACT","phone":"617-819-1389","email":"medinfo@sionnatx.com"}],"overallOfficials":[{"name":"Philip Ryan, MBBS, BMedSc, PhD, DPM, FFPM","affiliation":"Nucleus Network","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Nucleus Network","status":"RECRUITING","city":"Brisbane","state":"Queensland","zip":"4006","country":"Australia","contacts":[{"name":"Gloria Wong, MBBS, PhD, FRACP","role":"CONTACT","phone":"+61 (07) 3707 2720","email":"g.wong@nucleusnetwork.com.au"}],"geoPoint":{"lat":-27.46794,"lon":153.02809}},{"facility":"Nucleus Network","status":"RECRUITING","city":"Melbourne","state":"Victoria","zip":"3004","country":"Australia","contacts":[{"name":"Nucleus Network Melbourne","role":"CONTACT","phone":"+61 (03) 8593 9801","email":"melbourne@nucleusnetwork.com.au"},{"name":"Philip Ryan, MBBS, BMedSc, PhD, DPM, FFPM","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-37.814,"lon":144.96332}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D003550","term":"Cystic Fibrosis"}],"ancestors":[{"id":"D010182","term":"Pancreatic Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D007232","term":"Infant, Newborn, Diseases"}]}},"hasResults":false}
]}